Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)

Background Despite improved advances in graft-vs-host disease (GvHD) prophylaxis regimens and post-allogeneic hematopoietic cell transplant (HCT) supportive care, clinically significant acute GvHD still develops in approximately 30-50% of HCT recipients (Lazaryan A et al. BMT 2016) and often results...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-11, Vol.142 (Supplement 1), p.4944-4944
Hauptverfasser: Pourhassan, Hoda, Nguyen, Tina, Yang, Dongyun, Othman, Tamer, Koller, Paul B., Blackmon, Amanda, Agrawal, Vaibhav, Ball, Brian J., Amanam, Idoroenyi, Arslan, Shukaib, Otoukesh, Salman, Sandhu, Karamjeet S., Aldoss, Ibrahim, Ali, Haris, Salhotra, Amandeep, Aribi, Ahmed, Artz, Andrew, Becker, Pamela S., Pullarkat, Vinod, Stewart, Forest Marc, Smith, Eileen Patricia, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Al Malki, Monzr M.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4944
container_issue Supplement 1
container_start_page 4944
container_title Blood
container_volume 142
creator Pourhassan, Hoda
Nguyen, Tina
Yang, Dongyun
Othman, Tamer
Koller, Paul B.
Blackmon, Amanda
Agrawal, Vaibhav
Ball, Brian J.
Amanam, Idoroenyi
Arslan, Shukaib
Otoukesh, Salman
Sandhu, Karamjeet S.
Aldoss, Ibrahim
Ali, Haris
Salhotra, Amandeep
Aribi, Ahmed
Artz, Andrew
Becker, Pamela S.
Pullarkat, Vinod
Stewart, Forest Marc
Smith, Eileen Patricia
Stein, Anthony
Marcucci, Guido
Forman, Stephen J.
Nakamura, Ryotaro
Al Malki, Monzr M.
description Background Despite improved advances in graft-vs-host disease (GvHD) prophylaxis regimens and post-allogeneic hematopoietic cell transplant (HCT) supportive care, clinically significant acute GvHD still develops in approximately 30-50% of HCT recipients (Lazaryan A et al. BMT 2016) and often results in increased transplanted-related morbidity and mortality and deterioration of quality of life (Choi J et al. Blood 2012). Standard first-line treatment is high-dose glucocorticoids have been limited including recently approved JAK2 inhibitor (ruxolitinib). The utilization of combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab (a TNF-α inhibitor, INF) and basiliximab (an IL-2 receptor blocker, BAS), has had limited discussion in the literature despite common utilization. The primary objective of this retrospective study was to determine overall response rate (ORR) at days 7, 14 and 28 for CCBT. Secondary outcomes included non-relapse mortality (NRM), and overall survival (OS). Methods 60 patients who met the inclusion criteria were analyzed. Patients included were ≥18 years old and had undergone HCT using any donor or graft source with any conditioning regimen between 2010-2021 at City of Hope Medical Center in Duarte, CA. Patients had steroid refractory aGvHD, according to Mount Sinai Consortium guidelines (Harris AC et al. BMT 2016) and received at least one dose of BAS and at least one dose of INF. Patients with >1 allogeneic transplant, chronic GVHD including overlap syndrome, relapse of primary disease, graft loss, and glucocorticoid treatment for indications other than GVHD were excluded. Treatment BAS was administered intravenously as 20mg doses given first as loading doses on days 1 and 4. Subsequent doses were given weekly starting 7 days after the final loading dose (day 4). INF was administered as 10 mg/kg doses infused weekly. Tacrolimus, sirolimus and cyclosporine dosing and monitoring were performed in accordance with institutional policies. All patients had clinical presentation of SR-GVHD defined as ≥1 of the following: GVHD increasing in stage in any organ or developing in a new organ after 3 days of ≥2 mg/kg methylprednisolone (MSPE) or equivalent, GVHD that has not improved in stage in ≥1 organ after 7 days of ≥2 mg/kg MSPE or equivalent, development of GVHD in a new organ after ≥1 mg/kg MSPE or equivalent for skin GVHD or patients who progress during tapering before a 50% decrease in glucocorticoids is achieve
doi_str_mv 10.1182/blood-2023-190808
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2023_190808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000649712311545X</els_id><sourcerecordid>S000649712311545X</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1378-c88c082b0083a49f51f60ef83738f744ecb3a0a7667696472dd6a657db0e1d7f3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EEuXxAey8hIVhnKSxI1Y0hbYSElIfbCPHHoMhjZEdEP0NvpiUwpbV3BnpjGYOIWccLjmXyVXdeG9YAknKeAES5B4Z8GEiGUAC-2QAADnLCsEPyVGMLwA8S5PhgHyVfl27Fg0tN51_7RMdNV734YkunzGotw09L8vR8oKu4nY4UtE17tOtVU1Va-istX-t9YEuA6pujW1HvaWLDoN3hs3RBqU7HzZ0EpTt6COG-B7p1MeOjl1EFZGeL-Zs8jEdX5yQA6uaiKe_9Zis7m6X5ZTdP0xm5c090zwVkmkpNcikBpCpygo75DYHtDIVqbQiy1DXqQIl8lzkRZ6JxJhc5UNhakBuhE2PCd_t1cHHGNBWb6H_I2wqDtVWavUjtdpKrXZSe-Z6x2B_2IfDUEXtsNVoXEDdVca7f-hvGxh_yA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Pourhassan, Hoda ; Nguyen, Tina ; Yang, Dongyun ; Othman, Tamer ; Koller, Paul B. ; Blackmon, Amanda ; Agrawal, Vaibhav ; Ball, Brian J. ; Amanam, Idoroenyi ; Arslan, Shukaib ; Otoukesh, Salman ; Sandhu, Karamjeet S. ; Aldoss, Ibrahim ; Ali, Haris ; Salhotra, Amandeep ; Aribi, Ahmed ; Artz, Andrew ; Becker, Pamela S. ; Pullarkat, Vinod ; Stewart, Forest Marc ; Smith, Eileen Patricia ; Stein, Anthony ; Marcucci, Guido ; Forman, Stephen J. ; Nakamura, Ryotaro ; Al Malki, Monzr M.</creator><creatorcontrib>Pourhassan, Hoda ; Nguyen, Tina ; Yang, Dongyun ; Othman, Tamer ; Koller, Paul B. ; Blackmon, Amanda ; Agrawal, Vaibhav ; Ball, Brian J. ; Amanam, Idoroenyi ; Arslan, Shukaib ; Otoukesh, Salman ; Sandhu, Karamjeet S. ; Aldoss, Ibrahim ; Ali, Haris ; Salhotra, Amandeep ; Aribi, Ahmed ; Artz, Andrew ; Becker, Pamela S. ; Pullarkat, Vinod ; Stewart, Forest Marc ; Smith, Eileen Patricia ; Stein, Anthony ; Marcucci, Guido ; Forman, Stephen J. ; Nakamura, Ryotaro ; Al Malki, Monzr M.</creatorcontrib><description>Background Despite improved advances in graft-vs-host disease (GvHD) prophylaxis regimens and post-allogeneic hematopoietic cell transplant (HCT) supportive care, clinically significant acute GvHD still develops in approximately 30-50% of HCT recipients (Lazaryan A et al. BMT 2016) and often results in increased transplanted-related morbidity and mortality and deterioration of quality of life (Choi J et al. Blood 2012). Standard first-line treatment is high-dose glucocorticoids have been limited including recently approved JAK2 inhibitor (ruxolitinib). The utilization of combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab (a TNF-α inhibitor, INF) and basiliximab (an IL-2 receptor blocker, BAS), has had limited discussion in the literature despite common utilization. The primary objective of this retrospective study was to determine overall response rate (ORR) at days 7, 14 and 28 for CCBT. Secondary outcomes included non-relapse mortality (NRM), and overall survival (OS). Methods 60 patients who met the inclusion criteria were analyzed. Patients included were ≥18 years old and had undergone HCT using any donor or graft source with any conditioning regimen between 2010-2021 at City of Hope Medical Center in Duarte, CA. Patients had steroid refractory aGvHD, according to Mount Sinai Consortium guidelines (Harris AC et al. BMT 2016) and received at least one dose of BAS and at least one dose of INF. Patients with &gt;1 allogeneic transplant, chronic GVHD including overlap syndrome, relapse of primary disease, graft loss, and glucocorticoid treatment for indications other than GVHD were excluded. Treatment BAS was administered intravenously as 20mg doses given first as loading doses on days 1 and 4. Subsequent doses were given weekly starting 7 days after the final loading dose (day 4). INF was administered as 10 mg/kg doses infused weekly. Tacrolimus, sirolimus and cyclosporine dosing and monitoring were performed in accordance with institutional policies. All patients had clinical presentation of SR-GVHD defined as ≥1 of the following: GVHD increasing in stage in any organ or developing in a new organ after 3 days of ≥2 mg/kg methylprednisolone (MSPE) or equivalent, GVHD that has not improved in stage in ≥1 organ after 7 days of ≥2 mg/kg MSPE or equivalent, development of GVHD in a new organ after ≥1 mg/kg MSPE or equivalent for skin GVHD or patients who progress during tapering before a 50% decrease in glucocorticoids is achieved. Results The median age was 53 years (range, 5-78) at time of HCT. Of 60 patients, 65% were males and with 18.3% of male patients receiving grafts from female donor. HCT-CI at the time of HCT was 3 or more in 47% of the patients. Conditioning for those patients was ablative in 43.3% of patients with 76.7% of patients receiving PBSC grafts from mostly MSD/MUD in 75% of patients. Most patients had grade 3 or 4 overall acute GVHD (grade 3: n=35, 58.3%, grade 4: n=20, 33.3%). Median time to start of BAS after start of steroid was 7 days while time to start of INF after steroid was 11 days. Ruxolitinib was initiated in 33.3% (20/60) of patients prior to CCBT. ORR for CCBT therapy at day 7, 14, and 28 were 28.3% (17/60; CR 5.0%), 38.3% (23/60; CR 11.7%), and 38.3% (23/60; CR 23.3%), respectively. Patients who received ruxolitinib prior to CCBT had lower ORR (25%) compared to those who did not (47.5%). 37 patients died-20 of aGVHD, 4 of infection, 1 of sudden cardiac death and 1 of leukemia relapse. OS was 41.7% at 6 months and 36.5% at 12 months (Figure 1A). Cumulative incidence of NRM was 51.7% at 6 months and 55% at 12 months (Figure 1B). Cumulative incidence of any cGvHD was 33.6% at 12 months while it was 30% for extensive cGvHD at the same 12-month interval. In patients with and without ruxolitinib initiated prior to CCBT, OS at 12 months was 30% vs 40%, respectively (Figure 2A) while NRM at 12 months was 65% and 50%, respectively (Figure 2B). Conclusion CCBT has potential efficacy in steroid refractory aGVHD. The observed ORR is reflective of both advanced and highly refractory aGVHD with one-third of patients progressing on ruxolitinib. Given the favorable observed ORR in this difficult to treat population, CCBT is a potentially promising approach and suitable alternative in the second line or as salvage therapy in patients failing Ruxolitinib. Koller:treadwell therapuetics: Consultancy, Other: safety review committee; NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; takeda: Consultancy, Speakers Bureau. Sandhu:Autolus Therapeutics: Consultancy; City of Hope Medical Center: Current Employment. Aldoss:Amgen: Consultancy, Honoraria; Pfizer: Consultancy; Jazz: Consultancy; Sobi: Consultancy; KiTE: Consultancy; Takeda: Consultancy. Salhotra:Rigel Pharma: Research Funding; Jazz Pharma: Research Funding; Sobi: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; OrcaBio: Research Funding; Sanofi: Speakers Bureau; Kura Oncology: Research Funding; Gilead: Research Funding. Aribi:Kite, a Gilead Company: Consultancy; Seagen: Consultancy. Artz:Radiology Partner: Current equity holder in private company, Other: Spouse equity interest; Magenta Therapeutics: Other: Advisory Board; Abbvie: Consultancy; Astra Zeneca: Other: Advisory Board. Becker:Pfizer: Research Funding; Glycomimetics: Research Funding; Accordant Health Services: Membership on an entity's Board of Directors or advisory committees; GPCR Therapeutics: Research Funding. Pullarkat:Amgen: Consultancy, Speakers Bureau; Servier: Consultancy, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Stein:Sanofi: Current Employment, Current holder of stock options in a privately-held company. Marcucci:Ostentus Therapeutics: Current equity holder in private company, Research Funding. Nakamura:Sanofi: Consultancy; NCCN: Other: guideline panel for HCT; Blue Bird: Consultancy; Omeros: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: research collaboration; Napajen: Consultancy; International Consortium: Other: consortium chair; Miyarisan: Research Funding; Leukemia &amp; Lymphoma Society: Other: grant reviewer; BMT CTN Steering Committee: Membership on an entity's Board of Directors or advisory committees; Mt. Sinai: Other: Acute GVHD; NCTN Lymphoma Steering Committee: Membership on an entity's Board of Directors or advisory committees. Al Malki:Tscan: Consultancy. [Display omitted]</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2023-190808</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2023-11, Vol.142 (Supplement 1), p.4944-4944</ispartof><rights>2023 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Pourhassan, Hoda</creatorcontrib><creatorcontrib>Nguyen, Tina</creatorcontrib><creatorcontrib>Yang, Dongyun</creatorcontrib><creatorcontrib>Othman, Tamer</creatorcontrib><creatorcontrib>Koller, Paul B.</creatorcontrib><creatorcontrib>Blackmon, Amanda</creatorcontrib><creatorcontrib>Agrawal, Vaibhav</creatorcontrib><creatorcontrib>Ball, Brian J.</creatorcontrib><creatorcontrib>Amanam, Idoroenyi</creatorcontrib><creatorcontrib>Arslan, Shukaib</creatorcontrib><creatorcontrib>Otoukesh, Salman</creatorcontrib><creatorcontrib>Sandhu, Karamjeet S.</creatorcontrib><creatorcontrib>Aldoss, Ibrahim</creatorcontrib><creatorcontrib>Ali, Haris</creatorcontrib><creatorcontrib>Salhotra, Amandeep</creatorcontrib><creatorcontrib>Aribi, Ahmed</creatorcontrib><creatorcontrib>Artz, Andrew</creatorcontrib><creatorcontrib>Becker, Pamela S.</creatorcontrib><creatorcontrib>Pullarkat, Vinod</creatorcontrib><creatorcontrib>Stewart, Forest Marc</creatorcontrib><creatorcontrib>Smith, Eileen Patricia</creatorcontrib><creatorcontrib>Stein, Anthony</creatorcontrib><creatorcontrib>Marcucci, Guido</creatorcontrib><creatorcontrib>Forman, Stephen J.</creatorcontrib><creatorcontrib>Nakamura, Ryotaro</creatorcontrib><creatorcontrib>Al Malki, Monzr M.</creatorcontrib><title>Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)</title><title>Blood</title><description>Background Despite improved advances in graft-vs-host disease (GvHD) prophylaxis regimens and post-allogeneic hematopoietic cell transplant (HCT) supportive care, clinically significant acute GvHD still develops in approximately 30-50% of HCT recipients (Lazaryan A et al. BMT 2016) and often results in increased transplanted-related morbidity and mortality and deterioration of quality of life (Choi J et al. Blood 2012). Standard first-line treatment is high-dose glucocorticoids have been limited including recently approved JAK2 inhibitor (ruxolitinib). The utilization of combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab (a TNF-α inhibitor, INF) and basiliximab (an IL-2 receptor blocker, BAS), has had limited discussion in the literature despite common utilization. The primary objective of this retrospective study was to determine overall response rate (ORR) at days 7, 14 and 28 for CCBT. Secondary outcomes included non-relapse mortality (NRM), and overall survival (OS). Methods 60 patients who met the inclusion criteria were analyzed. Patients included were ≥18 years old and had undergone HCT using any donor or graft source with any conditioning regimen between 2010-2021 at City of Hope Medical Center in Duarte, CA. Patients had steroid refractory aGvHD, according to Mount Sinai Consortium guidelines (Harris AC et al. BMT 2016) and received at least one dose of BAS and at least one dose of INF. Patients with &gt;1 allogeneic transplant, chronic GVHD including overlap syndrome, relapse of primary disease, graft loss, and glucocorticoid treatment for indications other than GVHD were excluded. Treatment BAS was administered intravenously as 20mg doses given first as loading doses on days 1 and 4. Subsequent doses were given weekly starting 7 days after the final loading dose (day 4). INF was administered as 10 mg/kg doses infused weekly. Tacrolimus, sirolimus and cyclosporine dosing and monitoring were performed in accordance with institutional policies. All patients had clinical presentation of SR-GVHD defined as ≥1 of the following: GVHD increasing in stage in any organ or developing in a new organ after 3 days of ≥2 mg/kg methylprednisolone (MSPE) or equivalent, GVHD that has not improved in stage in ≥1 organ after 7 days of ≥2 mg/kg MSPE or equivalent, development of GVHD in a new organ after ≥1 mg/kg MSPE or equivalent for skin GVHD or patients who progress during tapering before a 50% decrease in glucocorticoids is achieved. Results The median age was 53 years (range, 5-78) at time of HCT. Of 60 patients, 65% were males and with 18.3% of male patients receiving grafts from female donor. HCT-CI at the time of HCT was 3 or more in 47% of the patients. Conditioning for those patients was ablative in 43.3% of patients with 76.7% of patients receiving PBSC grafts from mostly MSD/MUD in 75% of patients. Most patients had grade 3 or 4 overall acute GVHD (grade 3: n=35, 58.3%, grade 4: n=20, 33.3%). Median time to start of BAS after start of steroid was 7 days while time to start of INF after steroid was 11 days. Ruxolitinib was initiated in 33.3% (20/60) of patients prior to CCBT. ORR for CCBT therapy at day 7, 14, and 28 were 28.3% (17/60; CR 5.0%), 38.3% (23/60; CR 11.7%), and 38.3% (23/60; CR 23.3%), respectively. Patients who received ruxolitinib prior to CCBT had lower ORR (25%) compared to those who did not (47.5%). 37 patients died-20 of aGVHD, 4 of infection, 1 of sudden cardiac death and 1 of leukemia relapse. OS was 41.7% at 6 months and 36.5% at 12 months (Figure 1A). Cumulative incidence of NRM was 51.7% at 6 months and 55% at 12 months (Figure 1B). Cumulative incidence of any cGvHD was 33.6% at 12 months while it was 30% for extensive cGvHD at the same 12-month interval. In patients with and without ruxolitinib initiated prior to CCBT, OS at 12 months was 30% vs 40%, respectively (Figure 2A) while NRM at 12 months was 65% and 50%, respectively (Figure 2B). Conclusion CCBT has potential efficacy in steroid refractory aGVHD. The observed ORR is reflective of both advanced and highly refractory aGVHD with one-third of patients progressing on ruxolitinib. Given the favorable observed ORR in this difficult to treat population, CCBT is a potentially promising approach and suitable alternative in the second line or as salvage therapy in patients failing Ruxolitinib. Koller:treadwell therapuetics: Consultancy, Other: safety review committee; NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; takeda: Consultancy, Speakers Bureau. Sandhu:Autolus Therapeutics: Consultancy; City of Hope Medical Center: Current Employment. Aldoss:Amgen: Consultancy, Honoraria; Pfizer: Consultancy; Jazz: Consultancy; Sobi: Consultancy; KiTE: Consultancy; Takeda: Consultancy. Salhotra:Rigel Pharma: Research Funding; Jazz Pharma: Research Funding; Sobi: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; OrcaBio: Research Funding; Sanofi: Speakers Bureau; Kura Oncology: Research Funding; Gilead: Research Funding. Aribi:Kite, a Gilead Company: Consultancy; Seagen: Consultancy. Artz:Radiology Partner: Current equity holder in private company, Other: Spouse equity interest; Magenta Therapeutics: Other: Advisory Board; Abbvie: Consultancy; Astra Zeneca: Other: Advisory Board. Becker:Pfizer: Research Funding; Glycomimetics: Research Funding; Accordant Health Services: Membership on an entity's Board of Directors or advisory committees; GPCR Therapeutics: Research Funding. Pullarkat:Amgen: Consultancy, Speakers Bureau; Servier: Consultancy, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Stein:Sanofi: Current Employment, Current holder of stock options in a privately-held company. Marcucci:Ostentus Therapeutics: Current equity holder in private company, Research Funding. Nakamura:Sanofi: Consultancy; NCCN: Other: guideline panel for HCT; Blue Bird: Consultancy; Omeros: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: research collaboration; Napajen: Consultancy; International Consortium: Other: consortium chair; Miyarisan: Research Funding; Leukemia &amp; Lymphoma Society: Other: grant reviewer; BMT CTN Steering Committee: Membership on an entity's Board of Directors or advisory committees; Mt. Sinai: Other: Acute GVHD; NCTN Lymphoma Steering Committee: Membership on an entity's Board of Directors or advisory committees. Al Malki:Tscan: Consultancy. [Display omitted]</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAQRS0EEuXxAey8hIVhnKSxI1Y0hbYSElIfbCPHHoMhjZEdEP0NvpiUwpbV3BnpjGYOIWccLjmXyVXdeG9YAknKeAES5B4Z8GEiGUAC-2QAADnLCsEPyVGMLwA8S5PhgHyVfl27Fg0tN51_7RMdNV734YkunzGotw09L8vR8oKu4nY4UtE17tOtVU1Va-istX-t9YEuA6pujW1HvaWLDoN3hs3RBqU7HzZ0EpTt6COG-B7p1MeOjl1EFZGeL-Zs8jEdX5yQA6uaiKe_9Zis7m6X5ZTdP0xm5c090zwVkmkpNcikBpCpygo75DYHtDIVqbQiy1DXqQIl8lzkRZ6JxJhc5UNhakBuhE2PCd_t1cHHGNBWb6H_I2wqDtVWavUjtdpKrXZSe-Z6x2B_2IfDUEXtsNVoXEDdVca7f-hvGxh_yA</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>Pourhassan, Hoda</creator><creator>Nguyen, Tina</creator><creator>Yang, Dongyun</creator><creator>Othman, Tamer</creator><creator>Koller, Paul B.</creator><creator>Blackmon, Amanda</creator><creator>Agrawal, Vaibhav</creator><creator>Ball, Brian J.</creator><creator>Amanam, Idoroenyi</creator><creator>Arslan, Shukaib</creator><creator>Otoukesh, Salman</creator><creator>Sandhu, Karamjeet S.</creator><creator>Aldoss, Ibrahim</creator><creator>Ali, Haris</creator><creator>Salhotra, Amandeep</creator><creator>Aribi, Ahmed</creator><creator>Artz, Andrew</creator><creator>Becker, Pamela S.</creator><creator>Pullarkat, Vinod</creator><creator>Stewart, Forest Marc</creator><creator>Smith, Eileen Patricia</creator><creator>Stein, Anthony</creator><creator>Marcucci, Guido</creator><creator>Forman, Stephen J.</creator><creator>Nakamura, Ryotaro</creator><creator>Al Malki, Monzr M.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231102</creationdate><title>Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)</title><author>Pourhassan, Hoda ; Nguyen, Tina ; Yang, Dongyun ; Othman, Tamer ; Koller, Paul B. ; Blackmon, Amanda ; Agrawal, Vaibhav ; Ball, Brian J. ; Amanam, Idoroenyi ; Arslan, Shukaib ; Otoukesh, Salman ; Sandhu, Karamjeet S. ; Aldoss, Ibrahim ; Ali, Haris ; Salhotra, Amandeep ; Aribi, Ahmed ; Artz, Andrew ; Becker, Pamela S. ; Pullarkat, Vinod ; Stewart, Forest Marc ; Smith, Eileen Patricia ; Stein, Anthony ; Marcucci, Guido ; Forman, Stephen J. ; Nakamura, Ryotaro ; Al Malki, Monzr M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1378-c88c082b0083a49f51f60ef83738f744ecb3a0a7667696472dd6a657db0e1d7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pourhassan, Hoda</creatorcontrib><creatorcontrib>Nguyen, Tina</creatorcontrib><creatorcontrib>Yang, Dongyun</creatorcontrib><creatorcontrib>Othman, Tamer</creatorcontrib><creatorcontrib>Koller, Paul B.</creatorcontrib><creatorcontrib>Blackmon, Amanda</creatorcontrib><creatorcontrib>Agrawal, Vaibhav</creatorcontrib><creatorcontrib>Ball, Brian J.</creatorcontrib><creatorcontrib>Amanam, Idoroenyi</creatorcontrib><creatorcontrib>Arslan, Shukaib</creatorcontrib><creatorcontrib>Otoukesh, Salman</creatorcontrib><creatorcontrib>Sandhu, Karamjeet S.</creatorcontrib><creatorcontrib>Aldoss, Ibrahim</creatorcontrib><creatorcontrib>Ali, Haris</creatorcontrib><creatorcontrib>Salhotra, Amandeep</creatorcontrib><creatorcontrib>Aribi, Ahmed</creatorcontrib><creatorcontrib>Artz, Andrew</creatorcontrib><creatorcontrib>Becker, Pamela S.</creatorcontrib><creatorcontrib>Pullarkat, Vinod</creatorcontrib><creatorcontrib>Stewart, Forest Marc</creatorcontrib><creatorcontrib>Smith, Eileen Patricia</creatorcontrib><creatorcontrib>Stein, Anthony</creatorcontrib><creatorcontrib>Marcucci, Guido</creatorcontrib><creatorcontrib>Forman, Stephen J.</creatorcontrib><creatorcontrib>Nakamura, Ryotaro</creatorcontrib><creatorcontrib>Al Malki, Monzr M.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pourhassan, Hoda</au><au>Nguyen, Tina</au><au>Yang, Dongyun</au><au>Othman, Tamer</au><au>Koller, Paul B.</au><au>Blackmon, Amanda</au><au>Agrawal, Vaibhav</au><au>Ball, Brian J.</au><au>Amanam, Idoroenyi</au><au>Arslan, Shukaib</au><au>Otoukesh, Salman</au><au>Sandhu, Karamjeet S.</au><au>Aldoss, Ibrahim</au><au>Ali, Haris</au><au>Salhotra, Amandeep</au><au>Aribi, Ahmed</au><au>Artz, Andrew</au><au>Becker, Pamela S.</au><au>Pullarkat, Vinod</au><au>Stewart, Forest Marc</au><au>Smith, Eileen Patricia</au><au>Stein, Anthony</au><au>Marcucci, Guido</au><au>Forman, Stephen J.</au><au>Nakamura, Ryotaro</au><au>Al Malki, Monzr M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)</atitle><jtitle>Blood</jtitle><date>2023-11-02</date><risdate>2023</risdate><volume>142</volume><issue>Supplement 1</issue><spage>4944</spage><epage>4944</epage><pages>4944-4944</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Background Despite improved advances in graft-vs-host disease (GvHD) prophylaxis regimens and post-allogeneic hematopoietic cell transplant (HCT) supportive care, clinically significant acute GvHD still develops in approximately 30-50% of HCT recipients (Lazaryan A et al. BMT 2016) and often results in increased transplanted-related morbidity and mortality and deterioration of quality of life (Choi J et al. Blood 2012). Standard first-line treatment is high-dose glucocorticoids have been limited including recently approved JAK2 inhibitor (ruxolitinib). The utilization of combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab (a TNF-α inhibitor, INF) and basiliximab (an IL-2 receptor blocker, BAS), has had limited discussion in the literature despite common utilization. The primary objective of this retrospective study was to determine overall response rate (ORR) at days 7, 14 and 28 for CCBT. Secondary outcomes included non-relapse mortality (NRM), and overall survival (OS). Methods 60 patients who met the inclusion criteria were analyzed. Patients included were ≥18 years old and had undergone HCT using any donor or graft source with any conditioning regimen between 2010-2021 at City of Hope Medical Center in Duarte, CA. Patients had steroid refractory aGvHD, according to Mount Sinai Consortium guidelines (Harris AC et al. BMT 2016) and received at least one dose of BAS and at least one dose of INF. Patients with &gt;1 allogeneic transplant, chronic GVHD including overlap syndrome, relapse of primary disease, graft loss, and glucocorticoid treatment for indications other than GVHD were excluded. Treatment BAS was administered intravenously as 20mg doses given first as loading doses on days 1 and 4. Subsequent doses were given weekly starting 7 days after the final loading dose (day 4). INF was administered as 10 mg/kg doses infused weekly. Tacrolimus, sirolimus and cyclosporine dosing and monitoring were performed in accordance with institutional policies. All patients had clinical presentation of SR-GVHD defined as ≥1 of the following: GVHD increasing in stage in any organ or developing in a new organ after 3 days of ≥2 mg/kg methylprednisolone (MSPE) or equivalent, GVHD that has not improved in stage in ≥1 organ after 7 days of ≥2 mg/kg MSPE or equivalent, development of GVHD in a new organ after ≥1 mg/kg MSPE or equivalent for skin GVHD or patients who progress during tapering before a 50% decrease in glucocorticoids is achieved. Results The median age was 53 years (range, 5-78) at time of HCT. Of 60 patients, 65% were males and with 18.3% of male patients receiving grafts from female donor. HCT-CI at the time of HCT was 3 or more in 47% of the patients. Conditioning for those patients was ablative in 43.3% of patients with 76.7% of patients receiving PBSC grafts from mostly MSD/MUD in 75% of patients. Most patients had grade 3 or 4 overall acute GVHD (grade 3: n=35, 58.3%, grade 4: n=20, 33.3%). Median time to start of BAS after start of steroid was 7 days while time to start of INF after steroid was 11 days. Ruxolitinib was initiated in 33.3% (20/60) of patients prior to CCBT. ORR for CCBT therapy at day 7, 14, and 28 were 28.3% (17/60; CR 5.0%), 38.3% (23/60; CR 11.7%), and 38.3% (23/60; CR 23.3%), respectively. Patients who received ruxolitinib prior to CCBT had lower ORR (25%) compared to those who did not (47.5%). 37 patients died-20 of aGVHD, 4 of infection, 1 of sudden cardiac death and 1 of leukemia relapse. OS was 41.7% at 6 months and 36.5% at 12 months (Figure 1A). Cumulative incidence of NRM was 51.7% at 6 months and 55% at 12 months (Figure 1B). Cumulative incidence of any cGvHD was 33.6% at 12 months while it was 30% for extensive cGvHD at the same 12-month interval. In patients with and without ruxolitinib initiated prior to CCBT, OS at 12 months was 30% vs 40%, respectively (Figure 2A) while NRM at 12 months was 65% and 50%, respectively (Figure 2B). Conclusion CCBT has potential efficacy in steroid refractory aGVHD. The observed ORR is reflective of both advanced and highly refractory aGVHD with one-third of patients progressing on ruxolitinib. Given the favorable observed ORR in this difficult to treat population, CCBT is a potentially promising approach and suitable alternative in the second line or as salvage therapy in patients failing Ruxolitinib. Koller:treadwell therapuetics: Consultancy, Other: safety review committee; NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; takeda: Consultancy, Speakers Bureau. Sandhu:Autolus Therapeutics: Consultancy; City of Hope Medical Center: Current Employment. Aldoss:Amgen: Consultancy, Honoraria; Pfizer: Consultancy; Jazz: Consultancy; Sobi: Consultancy; KiTE: Consultancy; Takeda: Consultancy. Salhotra:Rigel Pharma: Research Funding; Jazz Pharma: Research Funding; Sobi: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; OrcaBio: Research Funding; Sanofi: Speakers Bureau; Kura Oncology: Research Funding; Gilead: Research Funding. Aribi:Kite, a Gilead Company: Consultancy; Seagen: Consultancy. Artz:Radiology Partner: Current equity holder in private company, Other: Spouse equity interest; Magenta Therapeutics: Other: Advisory Board; Abbvie: Consultancy; Astra Zeneca: Other: Advisory Board. Becker:Pfizer: Research Funding; Glycomimetics: Research Funding; Accordant Health Services: Membership on an entity's Board of Directors or advisory committees; GPCR Therapeutics: Research Funding. Pullarkat:Amgen: Consultancy, Speakers Bureau; Servier: Consultancy, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Stein:Sanofi: Current Employment, Current holder of stock options in a privately-held company. Marcucci:Ostentus Therapeutics: Current equity holder in private company, Research Funding. Nakamura:Sanofi: Consultancy; NCCN: Other: guideline panel for HCT; Blue Bird: Consultancy; Omeros: Consultancy; Jazz Pharmaceuticals: Consultancy, Other: research collaboration; Napajen: Consultancy; International Consortium: Other: consortium chair; Miyarisan: Research Funding; Leukemia &amp; Lymphoma Society: Other: grant reviewer; BMT CTN Steering Committee: Membership on an entity's Board of Directors or advisory committees; Mt. Sinai: Other: Acute GVHD; NCTN Lymphoma Steering Committee: Membership on an entity's Board of Directors or advisory committees. Al Malki:Tscan: Consultancy. [Display omitted]</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2023-190808</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2023-11, Vol.142 (Supplement 1), p.4944-4944
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2023_190808
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Combined Cytokine Blocking Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft Versus Host Disease (SR-GvHD)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T20%3A47%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20Cytokine%20Blocking%20Therapy%20(CCBT)%20Using%20Basiliximab%20and%20Infliximab%20for%20Treatment%20of%20Steroid-Refractory%20Graft%20Versus%20Host%20Disease%20(SR-GvHD)&rft.jtitle=Blood&rft.au=Pourhassan,%20Hoda&rft.date=2023-11-02&rft.volume=142&rft.issue=Supplement%201&rft.spage=4944&rft.epage=4944&rft.pages=4944-4944&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2023-190808&rft_dat=%3Celsevier_cross%3ES000649712311545X%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S000649712311545X&rfr_iscdi=true